transfusion related acute lung injury trali l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Transfusion Related Acute Lung Injury (TRALI) PowerPoint Presentation
Download Presentation
Transfusion Related Acute Lung Injury (TRALI)

Loading in 2 Seconds...

play fullscreen
1 / 15

Transfusion Related Acute Lung Injury (TRALI) - PowerPoint PPT Presentation


  • 554 Views
  • Uploaded on

Transfusion Related Acute Lung Injury (TRALI). Alan E. Williams, Ph.D. Director, Division of Blood Applications Office of Blood Research and Review CBER, FDA Blood Products Advisory Committee, April 27, 2007. Issue for the BPAC .

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Transfusion Related Acute Lung Injury (TRALI)' - liam


Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
transfusion related acute lung injury trali

Transfusion Related Acute Lung Injury (TRALI)

Alan E. Williams, Ph.D.

Director, Division of Blood Applications

Office of Blood Research and Review

CBER, FDA

Blood Products Advisory Committee, April 27, 2007

issue for the bpac
Issue for the BPAC

FDA seeks to be advised whether available scientific data support the development of FDA policies on methods to reduce the incidence of TRALI

trali introduction
TRALI - Introduction
  • TRALI Criteria
    • Acute onset during or within 6 hours of transfusion
    • Clinical evidence of hypoxemia
    • Bilateral infiltrates on frontal chest radiograph
    • No evidence of left atrial hypertension (i.e. circulatory overload)
    • Absence of other attributable causes
  • Risk per transfusion est. 1/2500- 1/5000
  • Treatable with Supportive Care When Recognized
  • Leading Cause of Post-transfusion Fatalities Reported to FDA
mechanisms of trali
Mechanisms of TRALI
  • 45-60% of TRALI cases associated with neutrophil-specific antibodies (NSA) in donor
  • Donor antibodies to HLA Class I or Class II antigens also implicated
  • Allotypic leukocyte antibodies known to be stimulated by pregnancy and transfusion
transfusion products associated with reported fatalities due to trali fy 06
Transfusion Products Associated with Reported Fatalities Due to TRALI FY 06
  • FFP 24
  • RBC 6
  • Platelets, Pheresis 2
  • RBC & FFP 2
  • RBC & Cryo-poor Plasma 1
prior fda public discussions regarding trali
Prior FDA Public Discussions Regarding TRALI
  • Blood Products Advisory Committee - June 15, 2001

Should FDA consider regulatory interventions at this time to identify donors and/or donations with an increased risk for producing TRALI in a recipient?

1 – Yes

13 - No

  • October 2001 FDA Physician Letter to Improve TRALI Recognition
    • Increased fatality reports to FDA
recent observations regarding trali
Recent Observations Regarding TRALI
  • SHOT analysis and UK intervention study
    • TRALI incidence 5 – 7-fold higher following administration of high volume plasma units
    • UK Minimized use of FFP and buffy coat-derived platelets from female donors in October 2003. TRALI incidence in the UK subsequently declined dramatically.
  • 2004 Canadian TRALI Consensus Conference
    • Introduced standardized TRALI definitions. Recommended that blood collection agencies assess the value and cost of TRALI interventions
recent observations regarding trali9
Recent Observations Regarding TRALI

American Red Cross objectively assessed 550 systemwide probable TRALI cases (2003-2005)

  • Plasma transfusion was associated with 24/38 (63%) of probable TRALI fatalities

(observed TRALI fatalities 4.93/106 distributed components)

  • Platelets, Pheresis were associated with 5/38 (13%) of probable TRALI fatalities

(observed TRALI fatalities 3.12/106 distributed components)

  • Female donors were disproportionately implicated in TRALI
  • Limiting plasma from female donors might reduce as many as six recipient deaths annually in the ARC system
voluntary industry recommendations aabb association bulletin 06 07
Voluntary Industry RecommendationsAABB Association Bulletin #06-07
  • Blood collecting facilities should implement interventions to minimize the preparation of high plasma volume components from donors known to be leukocyte-alloimmunized or at increased risk of leukocyte alloimmunization.
  • Blood transfusion facilities should work toward implementing appropriate evidence-based hemotherapy practices in order to minimize unnecessary transfusion
  • Blood collection and transfusion facilities should monitor the incidence of reported TRALI and TRALI-related mortality.
voluntary interventions being discussed or implemented among the blood collection community
Voluntary Interventions Being Discussed (or Implemented) Among the Blood Collection Community
  • Deferral of donors implicated in previous TRALI cases
  • Preferential Use of Male Plasma for Transfusion
  • Selected Donor Testing for NSA and HLA antibodies

(e.g. female donors of Platelets, Pheresis)

  • Review of Evidence Supporting Appropriate Use of Plasma
  • Research
    • Mechanisms of TRALI pathogenesis
    • Prevalence of associated antibodies and other factors
    • Role of previous transfusion in WBC alloimmunization of donors
trali discussion agenda
TRALI Discussion Agenda

Introduction

Alan Williams, Ph.D., DBA, OBRR, FDA

Clinical and Laboratory Aspects of TRALI,

David Stroncek, M.D., National Institutes of Health

Current Use of Transfusable Plasma

Ravi Sarode, M.D., University of Texas Southwestern Medical Center

trali session agenda cont
TRALI Session Agenda (cont.)

Review of REDS-II LAPS Study on HLA and Granulocyte Antibody Prevalence in Blood Donors

Steven Kleinman, M.D., University of British Columbia

American Red Cross Experience with TRALI

Richard Benjamin, M.D., American Red Cross

America’s Blood Centers Experience with TRALI,

Celso Bianco, M.D., America’s Blood Centers

questions for the committee
Questions for the Committee:

Question 1. Do current scientific data support the concept that the following interventions will reduce the incidence of TRALI?

  • Use of predominantly male plasma for transfusion.
  • Non-use of plasma for transfusion from donors with a history of prior transfusion
  • Selective donor screening for anti-neutrophil or anti-HLA antibodies
questions for the committee15
Questions for the Committee

Question 2. Based upon available data, please comment on the effect on the US plasma supply of the following interventions

  • Use of predominantly male plasma for transfusion
  • Non-use of plasma for transfusion from donors with a history of prior transfusion
  • Selective donor screening for anti-neutrophil or anti-HLA antibodies